Roivant’s longer-term colitis data set a bar in emerging TL1A class
Shares rise after Phase IIb maintenance readout shows rising remission rates beyond induction period
New Phase IIb ulcerative colitis data showing rising remission rates over time suggest a molecule from Roivant and Pfizer has exceeded efficacy expectations, driving a gain in market cap of about $334 million and setting a bar for others in the class.
Management at Roivant Sciences Ltd. (NASDAQ:ROIV) had hoped that patients receiving TL1A inhibitor RVT-3101 through the later months of a 56-week study period would maintain an efficacy level seen in the TUSCANY-2 study’s initial 14-week induction phase. Data announced Thursday showed that in the study’s chronic phase, remission rates rose, along with rates of endoscopically observed improvement...